A Phase 1/2/3, Open-Label, Dose Escalation, Dose Expansion, and Randomized, Controlled Study to Evaluate the Safety and Efficacy of ATSN-201 Gene Therapy in Male Subjects with RS1-Associated X-linked Retinoschisis (LIGHTHOUSE) (ATSN-201-1 (LIGHTHOUSE))
Principal Investigator
Prof Dominik Fischer
Contact us
Email: ERGO@ouh.nhs.uk
IRAS number
1014080